InsiderTrades

Form 4 for BCAX Bicara Therapeutics Inc.

Accepted 2024-09-18 00:00:00 ET · period of report 2024-09-16 · accession 0000950170-24-107660 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2024-09-18 2024-09-16 BCAX FMR LLC See Remark 1 C - Cnv Deriv — +1.12M 1.12M New —
DMI 2024-09-18 2024-09-16 BCAX FMR LLC See Remark 1 C - Cnv Deriv — -1.12M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-09-16 C A 712,430 — 723,248 I F-Prime Capital Partners Life Sciences Fund VII LP — — (F1) On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
2 Common Common Stock 2024-09-16 C A 10,818 — 10,818 I F-Prime Capital Partners Life Sciences Fund VII LP — — (F1) On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
3 Common Common Stock 2024-09-16 C A 392,085 — 1,115,333 I F-Prime Capital Partners Life Sciences Fund VII LP — — (F1) On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
4 Derivative Series B Preferred Stock 2024-09-16 C D 712,430 — 0 I F-Prime Capital Partners Life Sciences Fund VII LP — · — to — 712,430 Common Stock (F1) On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
5 Derivative Series Seed Preferred Stock 2024-09-16 C D 10,818 — 0 I F-Prime Capital Partners Life Sciences Fund VII LP — · — to — 10,818 Common Stock (F1) On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
6 Derivative Series C Preferred Stock 2024-09-16 C D 392,085 — 0 I F-Prime Capital Partners Life Sciences Fund VII LP — · — to — 392,085 Common Stock (F1) On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.